Parkinson’s disease has long been a diagnosis of observation and inference. Doctors watched for tremor, rigidity, and slowness of movement, and only at autopsy could the telltale clumps of alpha-synuclein protein—the pathological signature of the disease—be confirmed inside the brain. That diagnostic fog may finally be lifting. A new five-year study drawing on the landmark Parkinson’s Progression Markers Initiative (PPMI) has followed patients whose disease was defined not by their symptoms alone, but by biology: a positive cerebrospinal fluid seed amplification assay, the test that detects misfolded alpha-synuclein circulating in the nervous system. The results, published in Annals of Clinical and Translational Neurology, offer one of the clearest longitudinal pictures yet of how biologically confirmed Parkinson’s disease actually progresses in the era of modern treatment—and the findings are already reshaping how scientists think about staging, enrollment in clinical trials, and the very definition of the disease.

The research team set out with two central questions. First, what happens clinically to patients who test positive for synuclein seeding in their spinal fluid over five years of careful observation? Second, does a patient’s baseline stage on a new biological staging system—the Neuronal Synuclein Disease Integrated Staging System, or NSD-ISS—predict how quickly they will cross meaningful clinical milestones? Both questions cut to the heart of a quiet revolution in neurology. For more than a century, Parkinson’s was classified by what patients looked like in the examination room. Now, thanks to validated biomarkers, researchers can classify it by what is happening at the molecular level, potentially years before disabling symptoms emerge.

The seed amplification assay, or SAA, is the technological engine behind this shift. The test exploits a peculiar property of misfolded alpha-synuclein: it acts as a template that recruits normal, healthy synuclein proteins and forces them to misfold as well, seeding the aggregates known as Lewy bodies that riddle the brains of Parkinson’s patients. In the laboratory, a tiny sample of cerebrospinal fluid is mixed with synthetic alpha-synuclein and monitored for hours. If pathological seeds are present, the reaction accelerates into a detectable fluorescence signal. The assay has been validated across multiple international cohorts and, critically, against postmortem brain tissue, giving neurologists a window into pathology they previously could only glimpse after death. A complementary technique—detecting phosphorylated alpha-synuclein in small skin biopsies—has added a second, less invasive line of biological evidence.

Armed with these tools, two research groups have proposed frameworks for redefining Parkinson’s disease biologically. The SynNeurGe criteria classify patients by the combined presence of pathological alpha-synuclein biomarkers, neuroimaging evidence of neurodegeneration, and disease-relevant genetic variants. The Neuronal Synuclein Disease criteria take a parallel approach, defining disease by the presence of pathological synuclein as measured by a validated biomarker, with or without evidence of dopaminergic dysfunction detected through dopamine transporter imaging. The integrated staging system then arranges these biological anchors along a seven-stage ladder: Stage 0 reserved for carriers of fully penetrant mutations in the SNCA gene; Stages 1A and 1B for people with synuclein pathology but no symptoms, depending on whether dopaminergic dysfunction is present; Stages 2A and 2B for those with subtle signs that stop short of functional impairment; and Stages 3 through 6 capturing progressively severe clinical disability.

PPMI, the international observational study launched in 2010, provided the ideal laboratory for testing whether this staging framework means anything in the real world. The researchers focused on the sporadic Parkinson’s cohort: participants diagnosed within two years of enrollment who had never taken dopaminergic medication, whose examinations showed cardinal motor features, and whose dopamine transporter scans confirmed the characteristic deficit in the striatum. Crucially, the team selected only those participants who met biological NSD criteria through a positive CSF seed amplification assay, recruited before 2020 to guarantee at least five years of follow-up. This design deliberately stripped away a longstanding source of noise in Parkinson’s research: the clinical heterogeneity that arises when a “Parkinson’s” diagnosis might actually encompass unrelated neurodegenerative processes that mimic the disease but follow entirely different biological courses.

Over the five-year observation window, participants underwent an unusually thorough annual workup. Motor and non-motor function was tracked with the Movement Disorders Society Unified Parkinson’s Disease Rating Scale across all four of its parts, alongside the Hoehn and Yahr staging scale and the Schwab and England activities of daily living score. Smell was measured with the University of Pennsylvania Smell Identification Test, autonomic function with the SCOPA-AUT, mood with the Geriatric Depression Scale, and REM sleep behavior disorder risk with a dedicated screening questionnaire. Cognition was assessed with the Montreal Cognitive Assessment and, from the study’s third year onward, formal clinician diagnoses of normal cognition, mild cognitive impairment, or dementia. Medication burden was quantified as levodopa equivalent daily dose, and dopamine transporter imaging was repeated at years one, two, and four, quantified both in the putamen—the region most affected in Parkinson’s—and across the striatum as a whole.

The broad message from the five-year trajectories is one of measurable, biologically anchored progression. Patients recruited as freshly diagnosed, biologically confirmed sporadic Parkinson’s patients showed the expected decline across motor scales and dopaminergic imaging, with the earlier PPMI analysis by Simuni and colleagues having already documented significant—though modest—correlation between worsening clinical scores and falling DAT binding over five years. What the new analysis adds is the biological filter: by restricting the cohort to synuclein-seeding-positive individuals, the study reduces the contamination from look-alike conditions that has historically muddied progression estimates. When a cohort is defined by its underlying pathology rather than its outward symptoms, the resulting disease course becomes a truer reflection of what alpha-synuclein itself does to the nervous system over time.

Perhaps the most consequential findings concern prediction. If the NSD-ISS staging system is to earn its place in research clinics and, eventually, in therapeutic trials, it must do more than organize patients neatly on a page—it must forecast what comes next. The study analyzed whether a patient’s baseline stage predicted survival and the time required to reach clinically meaningful disease milestones: crossing thresholds on the clinical rating scales, advancing in Hoehn and Yahr stage, slipping in daily living independence, or developing cognitive impairment. The logic is straightforward and powerful. A patient sitting at Stage 2B—with confirmed synuclein pathology, dopaminergic dysfunction, and subtle signs but no functional impairment—should, in theory, march down the staging ladder at a predictable pace. Demonstrating that baseline stage genuinely stratifies risk would give trial designers a rational tool for enrichment, allowing them to recruit patients at the stage where a candidate drug is most likely to show benefit.

That trial-design implication is not academic. Across neurodegenerative disease research, therapeutic development is pivoting decisively toward biomarker-defined enrollment. The bitter lessons of Alzheimer’s trials—where anti-amyloid therapies only proved effective once trials recruited based on biological confirmation rather than syndrome alone—have not been lost on the Parkinson’s community. Drugs targeting alpha-synuclein directly, whether through immunotherapy, aggregation inhibition, or other mechanisms, are entering trials that increasingly require positive seed amplification assays or other biological confirmation as a gate for entry. A validated staging system that predicts five-year trajectory would allow sponsors to select participants early enough in the disease process for neuroprotective strategies to matter, while reserving later-stage patients for symptomatic interventions. The five-year PPMI data provide exactly the kind of naturalistic benchmark that such enrichment strategies demand.

The study also marks a conceptual milestone: the description of Parkinson’s disease under contemporary management. Patients diagnosed today are treated differently than those diagnosed twenty years ago, and their disease course may differ as a result. Describing outcomes in a biologically defined, prospectively observed cohort establishes a modern baseline against which future disease-modifying therapies can be judged. When an experimental drug claims to slow progression, the comparison will be against trajectories like those documented here—precise, biomarker-anchored, and free of the diagnostic uncertainty that plagued earlier natural history studies. In that sense, the paper functions simultaneously as a clinical report and as a foundation stone for the next generation of Parkinson’s trials.

What emerges from five years of watching synuclein-positive patients is a disease that can now be seen, staged, and tracked before it fully announces itself. The combination of CSF seed amplification assays, dopamine transporter imaging, and structured clinical assessment has converted a syndrome defined in the examination room into a biological disease measurable in the laboratory. If the staging system validated in this cohort continues to predict who declines fastest and who reaches milestones soonest, neurologists may one day tell a newly diagnosed patient not only what they have, but with unprecedented confidence what lies ahead—and researchers may finally test neuroprotective drugs in the early biological window where they stand the best chance of changing the story. For a disease that has resisted precise definition since James Parkinson first described it in 1817, that is a transformation worth watching.

A medical report published earlier this week says a boy in the U.K. developed erythema ab igne, or "toasted skin syndrome," after resting a laptop on his abdomen for up to eight hours a day, often while it was charging. "The marks were described as being in a patch about 15 centimeters (six inches) wide, made of flat, reddish-brown 'interlacing lines forming irregular circles and a lace-like morphology,'" reports Ars Technica. From the report: Based on the appearance, the doctors started reconsidering some sort of bruising and started asking him more questions. This is when he mentioned that he was homeschooled and used a laptop for his schoolwork. He said he typically did his work by resting his laptop on his abdomen while he worked, sometimes for up to eight hours a day, and often while the laptop was charging. Then they understood what it was. The doctors diagnosed the boy with erythema ab igne (EAI), which translates from Latin as "redness from fire" and is also sometimes called "toasted skin syndrome." This is a skin condition caused by repeated, prolonged exposure to low-grade heat -- heat not hot enough to cause actual burns. It's most often seen in adults, and common causes include using heating pads or hot water bottles for chronic pain or sitting too close to space heaters. Some people also develop it from certain occupational hazards, like glassblowing and metal work. EAI produces a lace-like rash, just like the boy's. It's unclear how EAI develops exactly. But researchers hypothesize that chronic heat exposure leads to damage to superficial blood vessels and the release of red blood cells, forming the tell-tale red reticulated pattern. While the boy's condition looked ominous, the good news is that EAI is generally benign and reversible -- once you remove the heat source. For severe or long-term conditions, some pigmentation and scarring can remain. But the boy's parents checked back in over several months, reporting that the rash faded and then completely resolved. Hopefully, he also got some sort of laptop stand.

Read more of this story at Slashdot.

Twenty-five years after the September 11 terrorist attacks, researchers at the Icahn School of Medicine at Mount Sinai have uncovered evidence that the environments in which World Trade Center responders live today may be quietly shaping their risk of frailty, post-traumatic stress disorder, and depression. The study, published in Nature Communications, is the first to examine how neighborhood-level environmental exposures later in life may interact with the chemical and psychological injuries sustained during the disaster response, adding a new dimension to one of the most intensively studied disaster health cohorts in the world.

The research team analyzed data from 18,734 responders who both live in New York City and receive care through one of the World Trade Center Health Program Clinical Centers of Excellence. These responders represent a population that experienced an extraordinary confluence of toxic exposures—dust, combustion products, airborne particulates, and a cocktail of known and suspected carcinogens—alongside severe psychological trauma. While decades of prior research have documented elevated rates of respiratory disease, cancer, and mental illness in this group, far less attention had been paid to whether the everyday conditions of their neighborhoods might compound or buffer those effects as responders age.

To answer that question, the researchers linked each responder’s residential address to annual estimates of three environmental factors: air pollution, high ambient temperatures, and neighborhood greenness, the last typically quantified through satellite-derived vegetation indices. This exposure-assessment approach, common in the field of environmental epidemiology, allowed the team to characterize the conditions each participant encountered where they lived year after year, rather than relying on broad regional averages. The researchers then examined whether those exposures were associated with the probability of being classified as frail, and with diagnosed PTSD and depression.

The results were striking in their consistency. Responders living in hotter neighborhoods—areas that experience more extreme heat days, a burden that falls disproportionately on densely built urban districts with impervious surfaces and little tree canopy—showed an elevated risk of frailty, a geriatric syndrome marked by diminished physiological reserve and heightened vulnerability to stressors. Elevated concentrations of air pollution were likewise associated with increased risks of both frailty and adverse mental health outcomes. Frailty itself is increasingly understood as a whole-body phenomenon, involving chronic inflammation, immune dysregulation, and cumulative cellular wear, all of which are plausible biological pathways through which heat and pollution could accelerate aging.

The mental health findings carried equal weight. Higher pollution and heat exposure were associated with increased odds of PTSD and depression, while responders living in greener surroundings—those with more parks, trees, and vegetated land near their homes—showed lower risks of all three conditions. This inverse association with greenness aligns with a substantial body of literature suggesting that access to green space can reduce psychological stress, encourage physical activity, dampen inflammation, and moderate urban heat, though the observational design of the study means that causation cannot be definitively established.

Perhaps the most provocative finding concerned interaction effects. The researchers found that responders who had experienced higher levels of World Trade Center–related chemical and psychological exposure appeared more vulnerable to the effects of environmental stressors in their current neighborhoods. In other words, the disaster and the decades that followed may not be independent chapters in these individuals’ health histories. Instead, responders already carrying the biological imprint of trauma and toxic dust—including altered inflammatory profiles, epigenetic changes, and persistent hypothalamic-pituitary-adrenal axis dysregulation—may enter later life with less reserve to absorb additional environmental insults. Everyday exposures that might be merely uncomfortable for a healthy middle-aged adult could, for these individuals, translate into measurable acceleration of physical decline and psychological deterioration.

“Twenty-five years after 9/11, we are still learning about the factors that influence the health of those who responded to the attacks,” said Helena Furman Krasnov, PhD, postdoctoral researcher at the Icahn School of Medicine and the study’s first author. “Our findings suggest that everyday exposures, including heat, air pollution, and access to green space, may contribute to responders’ long-term physical and psychological well-being. Understanding these factors could help identify new opportunities to support healthy aging in this population.”

The study’s senior and corresponding author, Maayan Yitshak-Sade, MPH, PhD, Associate Professor of Environmental Medicine at Mount Sinai and a member of the Institute for Exposomic Research, framed the work within the broader exposome paradigm—the effort to capture the totality of environmental exposures an individual accumulates over a lifetime. “Our findings suggest that the health consequences of 9/11 may not end with the disaster itself,” she said. “For responders already carrying the biological effects of trauma and toxic exposures, everyday environmental conditions may represent an additional source of stress on the body and mind. These findings highlight the importance of considering where people live, not just what they experienced during the disaster.”

That framing underscores a conceptual shift in disaster medicine. Traditional models tend to treat a catastrophic event as a discrete exposure with a defined aftermath. The Mount Sinai findings instead suggest that disaster-related health effects may unfold across an entire life course, modified by conditions that have no obvious connection to the original event. A responder’s risk of frailty in 2026 may reflect not only the hours spent at Ground Zero, but also the temperature of the summers they have endured since, the particulate matter drifting through their streets, and whether a leafy park sits within walking distance of their apartment.

The study arrives at a moment when urban environmental health has become a pressing policy concern. Extreme heat now kills more Americans annually than any other weather phenomenon, and cities including New York have launched ambitious initiatives to expand tree canopy, create cool corridors, and retrofit public housing with resilient cooling infrastructure. Air pollution, even at levels within regulatory limits, continues to be linked to cardiovascular, respiratory, and neurocognitive harm. If the associations identified in this cohort hold up under further scrutiny, they could strengthen the case for targeted environmental interventions—not as amenities, but as clinical supports for a vulnerable population.

The implications also extend well beyond the World Trade Center community. The researchers point out that survivors and responders from other disasters—wildfires that blanket entire regions in smoke and ash, industrial accidents that release toxic plumes, building collapses that bury rescue workers in dust—may face the same dual burden of physical and psychological exposures that continues to shape health long after the initial event. Climate change is intensifying heat waves and wildfire seasons simultaneously, meaning that disaster-affected populations may increasingly find themselves living in precisely the kinds of hostile urban microclimates the study identifies as risky. The framework developed here could inform how health surveillance programs for disaster cohorts are designed, prompting them to collect residential and environmental data alongside clinical outcomes.

The authors are careful to note the study’s observational nature. Associations between neighborhood environment and health can be confounded by socioeconomic status, housing quality, access to care, and the self-selection of healthier individuals into greener, quieter neighborhoods. The investigators controlled for available covariates, and the sheer size of the cohort lends statistical power, but randomized evidence on green space exposure is practically impossible to generate, and residual confounding remains an inherent limitation of the design. Longitudinal follow-up, and ideally natural-experiment analyses—such as the addition of new parks or major infrastructure changes—will be needed to firm up causal inference.

That work is already on the horizon. The team plans to investigate whether beneficial environmental factors, including green space and access to healthy food, can actively reduce the long-term health effects associated with World Trade Center–related exposures—a question that shifts the framing from risk identification to potential intervention. If confirmatory studies support the protective role of greenness, the findings could justify clinical guidance for responders, and potentially for other disaster-exposed populations, that goes beyond medication and monitoring to encompass the places where patients live.

For a population that has already given so much and borne so much, the idea that healing might partly depend on the landscape outside the front door is both sobering and hopeful. It suggests that some of the damage inflicted on September 11, 2001 may not be fixed, but modifiable—and that the next chapter of care for responders could be written not only in clinics, but in city planning offices, park commissions, and the slow, patient work of greening the neighborhoods where aging heroes live out their lives.

Historic data and predictions suggest cases will rise in East Africa and southern regions, while the threat may ease in West and Central Africa.

Glioblastoma is one of the most aggressive and treatment-resistant brain cancers known to medicine, carrying a median survival of just 12–15 months, even with the best available care.

A newly identified link between amino acid metabolism and cholesterol production may help prostate tumors adapt to hormone therapy. Prostate cancer can find ways around treatments designed to deprive tumors of the hormones they need to grow. Weill Cornell Medicine investigators have now traced one possible route of resistance to amino acid metabolism, where a [...]

Thirty years after a small group of European professors of geriatric medicine first warned that the continent’s fastest-growing population was being cared for by physicians who had never been formally trained to care for them, the program they created to fix the problem is marking its anniversary with a scientific milestone of its own. A new special article published in European Geriatric Medicine documents the research output of the most recent graduating cohort of the European Academy for Medicine of Ageing, or EAMA, and in doing so offers a rare longitudinal measure of how a structured, pan-European leadership program in geriatric medicine translates into scholarly productivity, professional advancement and, ultimately, better care for older people.

The new paper, titled “‘Highlights of latest EAMA’: generation research outputs of the 30-year anniversary cohort,” was authored by Thomas Münzer of the Geriatric Clinic St. Gallen in Switzerland, Hannes B. Stähelin of Basel, and Barbara van Munster of the University of Groningen Medical School in the Netherlands, writing on behalf of the EAMA Board. It arrives at a moment when the demographic arithmetic of Europe has made the question of geriatric capacity more urgent than ever: the proportion of people over 65 continues to climb, multimorbidity, frailty and polypharmacy have become the daily reality of hospital medicine, and health systems across the continent still struggle to recruit and retain physicians trained specifically in the medicine of ageing. The article’s premise is simple but rarely examined with this degree of rigor — if you invest systematically in the education of mid-career geriatricians, what do you get back?

To understand the significance of the anniversary cohort’s research output, one has to go back to the early 1990s, when the group of European Professors in Medical Gerontology published a stark assessment in the journal Age and Ageing. Writing in 1994, Stähelin and colleagues documented that medical gerontology was taught unevenly, and in many countries not at all, in European medical schools. Geriatric medicine, despite being one of the few specialties whose patient population was guaranteed to expand every single year, was frequently a subordinate unit within internal medicine, staffed by physicians who had acquired their expertise on the job rather than through dedicated training. The professors’ conclusion was that Europe needed not merely more geriatricians but a new cadre of academic leaders — clinicians who could teach, publish, shape curricula and advocate for the specialty within their national health systems.

That diagnosis led, in 1995, to the founding of the European Academy for Medicine of Ageing, an intensive postgraduate program deliberately modeled on leadership academies rather than conventional continuing medical education. EAMA’s structure has remained remarkably stable across its three decades: a small, competitively selected cohort of physicians, typically already experienced clinicians, is brought together for a series of residential courses spread over roughly two years, interspersed with mentored projects that require participants to produce original scholarly work. The curriculum spans the full breadth of the medicine of ageing — from the biology of ageing and the physiology of frailty, through geriatric syndromes such as falls, delirium, incontinence and sarcopenia, to the organizational science of acute geriatric units, nursing home medicine, rehabilitation and end-of-life care. Crucially, faculty are drawn from across Europe, exposing participants to radically different national models of geriatric care and building a professional network that persists long after the formal courses end.

The “reloaded” reform of the program, described in a 2018 paper by Roller-Wirnsberger and colleagues in European Geriatric Medicine, formalized what three decades of experience had taught the academy’s faculty. That paper set out explicit competencies and standards for a European leadership program in geriatric medicine, defining what a graduate of EAMA should be able to do: not just diagnose and treat, but design services, lead multidisciplinary teams, mentor juniors, conduct and critique research, and represent the specialty at institutional and governmental levels. The competency framework aligned the academy with modern medical-education theory, in which learning objectives are specified in advance and assessed rather than assumed. It is against this framework that the anniversary cohort’s performance, as documented in the new article, can be read as an evaluation of the program itself.

The central finding of the new special article is that the latest cohort of EAMA graduates has generated a substantial body of research output — the “generation research outputs” of the title — spanning peer-reviewed publications, presentations and ongoing projects in geriatric medicine. Each participant in the program is expected to develop a scholarly project under faculty mentorship, moving from a research question through protocol design, data collection and analysis to presentation and, ideally, publication. For the 30-year anniversary cohort, the academy compiled and highlighted these outputs, creating what the authors describe as the “Highlights of latest EAMA” — a curated snapshot of what a single generation of emerging European geriatric leaders produced during and immediately after their training.

Why does this matter beyond the individual careers involved? The technical answer lies in how research capacity compounds. A single published paper changes one evidence base marginally; a cohort of trained researchers who continue publishing changes the trajectory of an entire specialty. Geriatric medicine has historically been under-represented in high-impact clinical research relative to the burden of disease it manages. Conditions such as delirium, frailty and multimorbidity were for decades excluded from major trials or treated as confounders rather than outcomes, precisely because the specialty lacked enough investigator-trained clinicians to insist on their inclusion. Programs like EAMA attack that bottleneck at its root: every graduate who learns to design a study, secure a mentor and navigate the publication pipeline becomes a node through which clinical questions from the bedside can flow into the literature and back.

The pedagogical machinery behind that outcome is worth examining, because it explains why the anniversary cohort’s productivity is treated by the authors as more than a curiosity. EAMA’s residential courses are built around case-based, small-group learning in which participants bring real clinical and organizational problems from their home institutions and work them through with international faculty. The mentored projects between courses impose deadlines and accountability — the two ingredients that, as anyone who has supervised doctoral students knows, most reliably convert good intentions into submitted manuscripts. The academy also functions as a peer-review incubator: draft papers are critiqued by senior European geriatricians before submission, giving participants exposure to the standards of international journals at a stage of their careers when feedback is most formative.

The anniversary article also carries a personal and institutional poignancy. Hannes B. Stähelin, one of the co-authors, is identified in the publication as deceased; he was among the founding professors whose 1994 analysis launched the academy, and his presence on the author line of a paper published in 2026 spans the full thirty-year arc of the program. The continuity from the GEPMG position paper through the 2002 retrospective review of the academy’s first years, published in Gerontology, through the 2018 competency framework, and now to this documentation of cohort research output, constitutes something rare in medical education: a thirty-year, multi-generation audit trail of a single intervention in specialty training, documented by the people who built it.

For health systems, the implications are concrete. Europe’s national models of geriatric care differ enormously — from the fully established departments of the United Kingdom and the Netherlands to countries where geriatrics is still fighting for recognition as an independent specialty. EAMA’s cohorts deliberately mix these national traditions, so that a geriatrician from a country without an acute geriatric unit model trains alongside colleagues who run such units daily. The research outputs of the anniversary cohort, the authors suggest, function as a form of technology transfer: projects conceived in one system are published in international journals and become adaptable blueprints for colleagues elsewhere. In an era when the European Union explicitly tracks health-workforce capacity, an academy that reliably produces clinicians who can lead services and generate evidence is a strategic asset, not a professional courtesy.

The article is also, implicitly, an argument about how educational interventions should be evaluated. Medical education research is notoriously dominated by satisfaction surveys and self-reported confidence measures, which correlate weakly with actual performance change. Research output — publications generated, projects completed, academic positions attained — is a harder, more objective endpoint, and the EAMA Board’s decision to compile and publish the anniversary cohort’s outputs signals a commitment to accountability by measurable results. It is a methodology other postgraduate leadership programs in medicine, from palliative care to rural health, could plausibly adopt: define the competencies, train against them, and then report what the trainees actually produced.

The publication timeline of the article itself — received in December 2025, revised in April 2026, accepted in June and published on 6 July 2026 in European Geriatric Medicine, the journal of the European Geriatric Medicine Society — places it squarely in the anniversary year it commemorates. As Europe’s population ages at a pace with no historical precedent, the question the founding professors asked in 1994 — who will teach the teachers, and who will lead the specialty? — has an answer that can now be pointed to in print: thirty years of EAMA cohorts, and a newest generation whose scholarly work is documented, highlighted and, the academy clearly hopes, replicated by the cohorts to come.

A silent liver-destroying virus continues to spread across the United States at an accelerating pace, even though the drugs that cure it have been on pharmacy shelves for nearly a decade. In a perspective article published in the Journal of General Internal Medicine, two University of California, Los Angeles physicians argue that the nation’s faltering response to hepatitis C could be rescued by borrowing the playbook that transformed the HIV epidemic, from community-based testing and rapid “test and treat” initiation to federally funded safety nets and a fundamental reframing of what treatment nonadherence actually means.

The paper, written by Dr. Anna C. Scialli of UCLA’s Division of General Internal Medicine and Dr. Tara Vijayan of the Division of Infectious Diseases, opens with a clinical vignette that captures the paradox of modern hepatitis C care. A 34-year-old man with a history of injection drug use and unstable housing arrived at a hospital with fever, fatigue, and shortness of breath, and was found to have Staphylococcus aureus endocarditis with septic emboli. Screening revealed chronic hepatitis C virus infection. He was eager to begin treatment, and during a 39-day admission that included respiratory failure management and tricuspid valve replacement, clinicians started him on glecaprevir-pibrentasvir, obtained through the institution’s specialty pharmacy because the drug was not on the hospital formulary. It is precisely this kind of opportunistic, in-hospital treatment that the authors want to make routine.

The numbers they cite are stark. Between 2015 and 2022, the United States saw an estimated twofold increase in acute hepatitis C infections, yet only about a third of insured individuals diagnosed with the virus receive treatment within a year of diagnosis. Up to four million Americans are believed to carry the virus. By contrast, in HIV care, where the “care cascade” framework originally took root, roughly 76 percent of people diagnosed with HIV receive care and 65 percent are virally suppressed. The cascade framework, which tracks patients through sequential steps of diagnosis, linkage to care, receipt of direct-acting antivirals, and achievement of sustained virologic response, has been adopted by hepatitis C elimination strategies, but outcomes at every step have persistently lagged behind HIV milestones.

On the surface, the two viruses could hardly be more different biologically. Untreated HIV progressively depletes CD4 lymphocyte counts, producing the opportunistic infections and malignancies that define AIDS, a disease that is fatal within years for all but a rare fraction, less than half a percent, of “long-term non-progressors.” Chronic hepatitis C, meanwhile, may smolder asymptomatically for decades, gradually driving liver inflammation and fibrosis, with an estimated 5 to 10 percent of patients developing cirrhosis after twenty years and a 1 to 3 percent cumulative rate of hepatocellular carcinoma after thirty years. But the authors emphasize that the two epidemics share a critical social anatomy: both concentrate in the most marginalized communities, among people with limited access to prevention and treatment and distinct socioeconomic disparities. Their public health histories, they argue, overlap enough to yield forty years of transferable lessons.

The parallels run deep from the very beginning. HIV was first observed in New York as early as 1978 but was not formally reported until 1981, when Los Angeles physicians described Pneumocystis pneumonia in five men who have sex with men in the CDC’s Morbidity and Mortality Weekly Report. By 1990, more than 100,000 Americans had died of AIDS, and the disease, pejoratively labeled a “gay cancer,” became a vehicle for stigma and the marginalization of sexual minorities. Hepatitis C followed an eerily similar timeline. First described in 1975 as “non-A, non-B hepatitis” among transfusion recipients, accounting for up to 90 percent of transfusion-associated hepatitis, it was not definitively identified until 1989, when researchers isolated HCV RNA and developed an antibody test. Widespread blood-supply screening followed by 1992, and screening recommendations evolved from risk-based targeting to universal one-time screening of all adults by 2020, as rising infection rates among younger people shifted the epidemic’s demographics.

Treatment histories also rhyme. HIV therapy evolved from poorly tolerated early regimens to the 1996 introduction of combination antiretroviral therapy, then single-tablet regimens in the 2000s that improved adherence and reduced toxicity, and most recently long-acting injectables such as cabotegravir and rilpivirine, which maintain viral suppression with dramatically reduced adherence barriers. Hepatitis C treatment traveled its own arc, from interferon-alpha with cure rates low enough and durations long enough, up to 72 weeks, to be nearly prohibitive, through pegylated interferon plus ribavirin combinations marked by flu-like symptoms, depression, and hemolytic anemia, to the revolutionary direct-acting antivirals of the 2010s. The pan-genotypic regimens first approved by the FDA in 2016, including glecaprevir-pibrentasvir and sofosbuvir-velpatasvir, now offer eight-to-twelve-week, once-daily courses with rare side effects, no laboratory monitoring, and cure in over 95 percent of those treated. Because the cure is short, simple, and complete, the authors note, the technical barriers to hepatitis C eradication should be far lower than for HIV. That they are not is the central problem.

The first lesson concerns testing. Only an estimated 55 percent of people with hepatitis C are aware of their diagnosis, compared with an estimated 87 percent of people living with HIV. In the HIV epidemic, the shift from risk-based testing toward universal opt-out screening, launched by the CDC in 2006 when 21 percent of infections were undiagnosed, helped reduce undiagnosed infections to 15 percent by 2015. Crucially, that progress was driven by low-barrier testing outside traditional health facilities: mobile clinics, emergency rooms, community health fairs, and inpatient units. For hepatitis C, the settings with the highest testing yields today are syringe service programs and clinics treating substance use disorder, but the authors insist these cannot be the only option, particularly since syringe service programs lack federal support. They advocate a broad test-and-treat strategy, including initiating direct-acting antivirals during hospital admission. Because most hospitals will not stock the drugs, they propose a practical mechanism: prescribing through a contracted specialty pharmacy that purchases medications at 340B pricing and delivers them to the bedside, stored securely on the ward much like an unavailable home medication.

The second lesson concerns insurance and funding. Many state Medicaid programs still impose sobriety requirements and fibrosis-stage restrictions on hepatitis C treatment, and states with such restrictions treat fewer patients, despite explicit recommendations from the Infectious Diseases Society of America and the American Association for the Study of Liver Diseases to remove them. Private insurers are even less transparent, denying more than half of hepatitis C treatment claims in one national specialty pharmacy cohort study. HIV care took a different path: the Ryan White CARE Act of 1990 created a federally funded safety net covering antiretroviral therapy for uninsured and underinsured patients, now supporting 82 percent of uninsured people living with HIV. Early hospital initiation of antiretroviral therapy has been shown to improve linkage to care, especially for patients with substance use disorder. No equivalent exists for hepatitis C, even though an estimated 60 percent of people with the virus are covered by public insurance, and the 2025 One Big Beautiful Bill cut nearly one trillion dollars from Medicaid over the coming decade. Meanwhile, budget pressures threaten HIV’s own safety net: as of February 2026, twenty states were tightening AIDS Drug Assistance Program eligibility, and models estimate up to a 73 percent increase in new HIV infections across thirty states if that funding disappears.

The third lesson is the most philosophical. Provider hesitancy, particularly toward people who use drugs, remains a powerful barrier to hepatitis C treatment, with physicians frequently citing concerns about nonadherence. Yet studies show people who use drugs complete hepatitis C treatment more than 96 percent of the time. HIV advocacy movements, notably ACT UP, forced a reframing: nonadherence was reinterpreted not as a moral failing of the patient but as a failure of systems in which marginalized groups face enormous barriers. Current CDC guidelines now explicitly state that homelessness, substance use, and mental health conditions are not justifiable reasons to defer antiretroviral therapy, and federally funded supports, from Ryan White case management and patient navigation to the Housing Opportunities for Persons with AIDS program, address the social determinants that undermine adherence. Peer navigation programs and drug user unions are emerging as hepatitis C analogs, but without matching federal investment.

The Norway-based OPPORTUNI-C trial provides the empirical anchor for the authors’ central proposal: among people who inject drugs, 68 percent of those who began hepatitis C treatment while hospitalized completed it, compared with just 35 percent of those referred to outpatient care. For a population with frequent admissions and siloed inpatient care, the hospital bedside may be the single best opportunity to deliver a cure. As antiretroviral therapy became simpler and its community-level benefits clear, the authors write, reducing time to treatment initiation became not merely a public health measure but a moral imperative. With a twelve-week cure available, they argue, hepatitis C elimination now depends on treating patients where they are.

Idiopathic pulmonary fibrosis, a relentlessly progressive and fatal scarring disease of the lungs, has long frustrated clinicians with only two approved drugs that slow but cannot reverse its course. Now, a team of researchers in Taiwan has identified a surprising new player in the disease’s destructive machinery: doublecortin-like kinase 1, or DCLK1, a kinase better known for its role in cancer stem cells. Their study, published in the Journal of Biomedical Science, demonstrates that DCLK1 drives fibroblast activation in the lung and that blocking it—either genetically or with an oral inhibitor—slows fibrosis and preserves lung function in mice. The findings position DCLK1 as a promising therapeutic target in one of medicine’s most stubborn diseases.

The research, led by Lee-Yuan Lin, Wun-Hao Cheng, Chien-Huang Lin and Bing-Chang Chen of Taipei Medical University, together with collaborators at National Taiwan University Hospital and Universitas Gadjah Mada, began with a question that has lingered in the literature. Gene expression analyses had previously hinted that DCLK1 might be implicated in IPF, and earlier work reported that the kinase is markedly enhanced in the alveolar epithelial cells of patients with pulmonary fibrosis and in mice with bleomycin-induced fibrosis. But its function in fibroblast activation—the cellular engine of fibrosis—had remained unexplained.

To begin untangling that role, the team mined a publicly available single-cell RNA sequencing data set containing more than 312,000 cells from healthy lungs, IPF lungs, and lungs with chronic obstructive pulmonary disease. After stringent quality control filtering, they focused on roughly 240,000 cells from the control and IPF groups and mapped DCLK1 expression across the major lung cell lineages: epithelial, endothelial, lymphoid, myeloid, and stromal cells. The signal was unmistakable. DCLK1 was expressed across many cell populations, but the highest expression appeared in the stromal compartment, particularly in myofibroblasts—the specialized, contractile fibroblasts that churn out the extracellular matrix and stiffen lung tissue in IPF.

Human tissue told the same story. The researchers examined lung samples from eleven patients with IPF, obtained during lung transplantation or surgery, alongside fourteen nonfibrotic control samples. Histological staining with hematoxylin and eosin and Masson trichrome confirmed the expected picture of interstitial consolidation and collagen deposition in the IPF specimens. More importantly, immunohistochemistry revealed that both total DCLK1 and its phosphorylated, activated form were significantly upregulated in the fibrotic lung interstitium compared with control tissue. DCLK1, in other words, was not merely present in scarred lungs—it was switched on.

DCLK1 is an intriguing molecule to find at the center of a fibrotic process. It is a serine/threonine kinase belonging to the calcium/calmodulin-dependent kinase family, distinguished by two microtubule-binding domains. In oncology, DCLK1 overexpression has been documented in colorectal, pancreatic, gastric, renal, and hepatocellular carcinomas, where it correlates with poor prognosis, high recurrence, and metastasis, promoting tumor initiation and the epithelial–mesenchymal transition in cancer stem cells. It has also been linked to inflammatory signaling in SARS-CoV-2 infection, where inhibiting it blocks proinflammatory caspase-1/interleukin-1β signaling. The new study extends this portfolio of mischief to the fibrotic lung.

To test causality rather than mere correlation, the researchers turned to mice. They crossed animals carrying loxP sites flanking exon 3 of the DCLK1 locus with Pgk1-RFP-Cre/ERT2 transgenic mice, generating a system in which tamoxifen administration triggers global deletion of the Dclk1 gene. When these DCLK1 knockout mice and littermate controls were given intratracheal bleomycin, a chemotherapy drug used to induce pulmonary fibrosis in laboratory animals, the difference was striking. Knockout mice showed far less lung infiltration and collagen deposition, reduced numbers of cells staining positive for DCLK1 together with fibroblast surface protein and alpha-smooth muscle actin, and significantly lower levels of the profibrotic proteins fibronectin, α-SMA, and connective tissue growth factor, or CTGF.

The protective effect extended well beyond molecular markers. Using the FlexiVent FX system to measure lung mechanics, the team found that bleomycin treatment significantly reduced respiratory system compliance and pressure–volume performance and increased the normalized work of breathing in control mice—hallmarks of a stiffening, fibrotic lung. In the DCLK1 knockout animals, these functional deficits were substantially attenuated. In vivo microcomputed tomography, acquired at 34.75-micrometer voxel resolution, painted the morphological counterpart: bleomycin caused parenchymal destruction and volume loss in control lungs, while knockout mice retained lung structure and volume. Density histograms shifted toward fibrotic tissue in wild-type animals but stayed largely preserved in the knockouts, and peripheral blood neutrophil percentages, which climbed after bleomycin injury, were significantly reduced in the knockout group.

With the in vivo evidence established, the investigators dissected the molecular wiring in cultured normal human lung fibroblasts. Transforming growth factor beta, the master profibrotic cytokine, induced DCLK1 phosphorylation within 30 minutes and DCLK1 expression within 8 hours. Chromatin immunoprecipitation assays showed that after TGF-β stimulation, both Smad3—the canonical transcriptional mediator of TGF-β signaling—and the nuclear factor kappa B subunit p65 enriched at the DCLK1 promoter, indicating that TGF-β switches on DCLK1 through both Smad-dependent and noncanonical NF-κB pathways. Silencing DCLK1 with small interfering RNA then blunted the fibroblast’s profibrotic response, reducing TGF-β-induced expression of fibronectin, collagen 1A1, α-SMA, and CTGF.

The pathway, however, does not stop there. The team found that TGF-β also phosphorylated Akt, and that transfecting fibroblasts with a dominant-negative Akt construct reduced TGF-β-induced DCLK1 phosphorylation and the expression of fibronectin and CTGF—placing Akt upstream of DCLK1. Downstream, DCLK1 knockdown reduced Smad3 phosphorylation while DCLK1 overexpression enhanced it. Coimmunoprecipitation revealed a physical association between DCLK1 and Smad3, and immunofluorescence microscopy showed the two proteins colocalizing in the nucleus within 30 minutes of TGF-β treatment. A ChIP assay using a DCLK1 antibody pulled down DNA from the Smad3-binding region of the CTGF promoter, and pretreatment with the selective DCLK1 inhibitor DCLK1-IN-1 reduced TGF-β-induced CTGF expression. Together, the results sketch an Akt/DCLK1/Smad3 axis through which TGF-β drives the production of connective tissue growth factor, a potent profibrotic mediator.

The clinical payoff came in the pharmacological arm of the study. Mice receiving oral DCLK1-IN-1 at 10 milligrams per kilogram daily, beginning on day 7 after bleomycin instillation and continuing until day 28, showed visibly reduced fibrotic progression on histology, lower expression of fibronectin, α-SMA, and CTGF in lung tissue and lysates, preserved pulmonary compliance, improved pressure–volume loops, and reduced work of breathing. Serial microCT scans on days 7, 17, and 27 documented less severe fibrotic remodeling in the treated animals, with lung attenuation histograms showing a smaller fraction of dense, nonaerated voxels. Blood neutrophil counts were also lower. In short, a pill-like oral inhibitor measurably slowed the disease in a model that mirrors the human condition.

The implications are significant because the current therapeutic landscape for IPF is so thin. Only nintedanib, a tyrosine kinase inhibitor targeting growth factor receptors, and pirfenidone, which suppresses TGF-β production and activity, are approved by the US Food and Drug Administration, and both merely slow progression. The recent failure of pamrevlumab, a monoclonal antibody against CTGF, in the phase 3 ZEPHYRUS-1 trial suggested that targeting downstream fibrotic end products alone may be insufficient—pointing to the value of upstream signaling regulators such as DCLK1. Adding to the appeal, a DCLK1 inhibitor has already been shown to prevent inflammatory responses in acute lung injury, hinting at dual anti-fibrotic and anti-inflammatory potential.

The authors are careful to note limitations. DCLK1 is expressed across multiple lung cell types, and the tamoxifen-inducible knockout used here was global rather than cell-type-specific, so the contributions of fibroblasts versus epithelial, endothelial, and immune cells could not be fully separated. Human control tissue, as in most fibrosis studies, came from heterogeneous sources, including tumor-adjacent lung. The precise subcellular mechanics of the DCLK1–Smad3 interaction, whether DCLK1 inhibition can promote fibrosis resolution rather than merely slow progression, and the systemic safety of long-term DCLK1 blockade—all relevant given the kinase’s role in cancer and other processes—remain open questions.

Even so, the convergence of evidence is striking: DCLK1 is upregulated in human IPF, amplified in experimental fibrosis, mechanistically coupled to the TGF-β–Smad3 engine of fibroblast activation, and its suppression by both genetics and a small molecule preserves lung structure and function. What began as a cancer stem cell marker has now emerged, unexpectedly, as a central node in the scarring of the lung—offering fresh hope that a disease long considered irreversible may one day be stopped at its molecular source.

In a finding that could reshape how ophthalmologists think about one of the most delicate complications of corneal surgery, a team of computational engineers has built the first detailed computer model of a human eye in which the Descemet membrane—the paper-thin basement layer at the back of the cornea—has become detached. By simulating the fluid–structure interaction between the aqueous humor sloshing inside the eye’s anterior chamber and the flexible, detached membrane itself, the researchers have produced quantitative predictions about the mechanical stresses such a detachment imposes, and about how different transplanted corneas might alter those stresses during post-operative thermal therapy.

The study, published in the Annals of Biomedical Engineering, addresses a long-standing blind spot in ocular biomechanics. Detachment of the Descemet membrane is a recognized complication of cataract surgery, corneal transplantation and certain corneal dystrophies, and it can cause significant corneal swelling and vision loss if the membrane does not reattach. Yet most previous computational examinations of the anterior chamber have treated the eye’s interior as rigid-walled plumbing, focusing on fluid flow or heat transfer while excluding the complex two-way coupling between the intraocular fluid and the fragile ocular structures suspended within it. The new work changes that by modeling the detached Descemet membrane as a deformable, elastic solid that bends, stretches and deforms under the pressure and shear of the aqueous humor flowing around it.

The researchers, led by Ammar I. Alsabery of the Islamic University in Najaf, Iraq, together with colleagues from the University of Basrah, King Khalid University in Saudi Arabia, Saveetha School of Engineering in India, and Universiti Kebangsaan Malaysia, employed a coupled numerical scheme that solves simultaneously for the buoyancy-driven flow of aqueous humor and for the structural deformation of the membrane. The geometry represents the anterior chamber—the fluid-filled space between the cornea and the iris—with a warm region corresponding to the lens contact zone held at an isothermal hot temperature, mimicking the thermal gradients that arise in ocular warming therapies and in normal physiological conditions.

At the heart of the analysis is the Rayleigh number, a dimensionless parameter that governs the strength of natural convection: warmer, less dense fluid rises while cooler fluid sinks, generating circulating currents within the chamber. The team varied the Rayleigh number across three orders of magnitude, from 10³ to 10⁶, which corresponds to temperature differences spanning from a fraction of a degree to 250 Kelvin. This range deliberately encompasses both the mild thermal gradients present in the living eye and the much more aggressive temperature differences applied during clinical thermal therapy of the cornea, allowing the same model to speak to both resting physiology and active treatment.

Equally central to the study is the elasticity modulus of the detached membrane. The researchers swept this property across nine orders of magnitude, from 10⁸ to 10¹¹, a range designed to represent everything from highly compliant, freshly detached tissue to the much stiffer mechanical character of donor corneal tissue used in transplantation. Because the Descemet membrane’s stiffness varies with age, disease state and surgical history, this parametric approach lets the model answer a question that clinicians genuinely care about: does the type of cornea grafted into a patient change the mechanical load experienced by a detached membrane during recovery? The answer, according to the simulations, is nuanced. The cornea type does affect the stress imparted on the detached Descemet membrane, but it does not affect the thermal characteristics of the anterior chamber or the overall displacement behavior within it. In other words, stiffer transplanted tissue changes the mechanical environment at the membrane itself without appreciably altering the convective heat transfer patterns of the aqueous humor circulating beneath it.

The fluid dynamics of the anterior chamber turned out to be far more sensitive to geometry than to tissue stiffness. One of the most striking results concerns the iris, the pigmented diaphragm whose length in the model determines the extent of the hot, isothermal contact region associated with the lens. When the team simulated a shrinkage of the iris—effectively reducing the length of the contacting part of the lens held at the hot temperature—they found that the convective thermal characteristic of the anterior chamber rose by approximately 78 percent. This dramatic enhancement arises because the reduced iris length reshapes the buoyancy-driven circulation cells, allowing warmer fluid to travel more freely and exchange heat more efficiently with its surroundings. For clinicians, the implication is that the geometry of the anterior chamber, shaped in part by the iris and the lens, is a first-order determinant of how heat is distributed during thermal therapy, potentially more important than the material properties of the graft itself.

The temperature difference applied during thermal therapy also proved to be a powerful lever. Raising the applied thermal gradient from 2.5 Kelvin to 25 Kelvin—a tenfold increase—promoted heat transfer within the anterior chamber by 47.6 percent. While the scaling is sublinear rather than directly proportional to the temperature difference, the result confirms that modest increases in therapeutic temperature can yield meaningful gains in convective heat delivery without requiring a hundredfold jump in applied thermal load. The finding offers a quantitative framework for calibrating thermal treatments of the anterior segment: therapy protocols could, in principle, be tuned to achieve target heat transfer rates while respecting the narrow thermal safety margins of living ocular tissue.

Technically, the simulations belong to a class of problems known as fluid–structure interaction, or FSI, in which the fluid equations and the solid mechanics equations are coupled and solved together rather than in isolation. In this case, the aqueous humor—an essentially water-like fluid—drives natural convection under the influence of gravity, while the detached Descemet membrane responds to the pressure and viscous stresses exerted by that flow. The membrane’s deformation, in turn, modifies the shape of the fluid domain, feeding back into the flow field. This two-way coupling is computationally demanding but essential, because a rigid-wall approximation would entirely miss the bending and displacement of the detached membrane, along with the localized stress concentrations that could determine whether the membrane reattaches, tears further, or remains stable during healing. The methodology builds on the team’s earlier FSI studies of flexible fins, baffles and partitions in convective systems, as well as their prior work applying FSI modeling to blood flow in abdominal aortic aneurysms under thermal treatment, adapting those engineering tools to the peculiar geometry and physiology of the human eye.

The choice to represent the detached Descemet membrane as a flexible structure rather than a fixed boundary is what gives the study its clinical bite. Prior models of aqueous humor flow, including foundational work on fluid flow in the anterior chamber of the human eye published decades ago, captured the buoyancy-driven currents but assumed static, impermeable walls. By letting the membrane move, the new simulations capture the interplay between hemodynamics-like fluid loading and tissue compliance—precisely the interplay that governs how a detached membrane flutters against the aqueous humor, how stresses concentrate at its edges and attachments, and how different graft stiffnesses redistribute those stresses across the corneal structure. The team’s results suggest that surgeons and biomaterials scientists selecting corneal grafts for patients prone to Descemet membrane detachment could use stress predictions of this kind to weigh graft stiffness as part of the decision, even though the overall thermal environment of the chamber will remain largely unchanged.

Beyond transplantation, the model has direct relevance to thermal therapy of the eye, a class of treatments in which controlled warming is applied to manage conditions of the anterior segment. Because the simulations connect an easily controlled clinical variable—the applied temperature difference—to a measurable outcome in convective heat transfer, and because they quantify the role of iris geometry in shaping the thermal flow field, they provide a template for patient-specific treatment planning. A clinician armed with imaging of a patient’s anterior chamber geometry could, in principle, use models of this type to predict how a planned thermal protocol will distribute heat in the presence of a detached membrane, and whether the resulting stresses on the membrane fall within tolerable limits.

The work is not without its simplifications, as the authors themselves frame the study as an evaluation of corneal transplantation processes rather than a complete clinical simulator. The anterior chamber geometry is idealized, the aqueous humor is treated with standard transport properties, and the elasticity modulus range, while broad, samples the problem in parametric steps rather than matching every individual patient’s tissue. Real eyes also feature aqueous production and drainage, blinking, saccadic motion and ocular pulse effects that a steady natural-convection FSI model does not capture. Nonetheless, the paper’s central contribution—demonstrating that corneal stiffness governs membrane stress while iris geometry and thermal gradient govern heat transfer—stands as a clean separation of effects that future, more detailed models will need to reproduce.

The research was supported by the Universiti Kebangsaan Malaysia Research Grant GP-2024-K006388 and by the Deanship of Research and Graduate Studies at King Khalid University through a large Research Group Project. As computational biomechanics continues to migrate from engineering journals into clinical planning, studies like this one mark a shift toward treating the eye not as a static optical instrument but as a living, deformable, fluid-filled machine—one in which a membrane thinner than a human hair can dominate the mechanical conversation, and where the difference between a compliant and a stiff cornea may one day inform the surgeon’s graft choice.

Endometriosis, a chronic inflammatory condition affecting an estimated one in ten women of reproductive age, has long frustrated clinicians with its stubborn tendency to recur despite surgery and hormone therapy. A new review published in Reproductive Sciences argues that the answer to this therapeutic failure may lie in a single transcription factor: ZEB1, or Zinc Finger E-Box Binding Homeobox 1. Written by Gaurav Doshi and Sanket Shirodkar of SVKM’s Dr. Bhanuben Nanavati College of Pharmacy in Mumbai, the review synthesises evidence from across the field to position ZEB1 as a master molecular integrator—converging hormonal, inflammatory and epigenetic signals into a single programme that drives lesion establishment, invasiveness and drug resistance.

The biological centrepiece of the review is epithelial–mesenchymal transition, or EMT, the process by which epithelial cells lose their adhesive, stationary character and acquire the migratory, invasive traits of mesenchymal cells. In endometriosis, EMT is thought to be essential for the survival of endometrial cells that reflux into the pelvic cavity during menstruation and subsequently implant on peritoneal surfaces, ovaries and other ectopic sites. ZEB1 sits at the apex of this programme. It suppresses CDH1, the gene encoding E-cadherin, the principal adhesion molecule holding epithelial sheets together, and in doing so dismantles the cell–cell junctions that would otherwise keep ectopic cells anchored and vulnerable. The review details how ZEB1 accomplishes this repression by recruiting chromatin-remodelling machinery, notably the SWI/SNF ATPase subunit BRG1, to the E-cadherin promoter, effectively silencing it epigenetically. The result is a stabilised mesenchymal differentiation that permits attachment, invasion and, ultimately, the vascularisation required for a lesion to persist.

Crucially, the authors argue that ZEB1 is not merely one EMT factor among many, such as SNAI1, SNAI2 or its paralog ZEB2, but a systems-level hub. Immunohistochemical and molecular studies have repeatedly shown selective upregulation of ZEB1 in ectopic endometriotic lesions compared with matched eutopic endometrium, and its expression is particularly pronounced in deep infiltrating disease. One frequently cited clinical study found ZEB1 expression to be a potential indicator of invasive endometriosis, while a pilot investigation of different disease phenotypes has extended these observations across superficial, ovarian and deep infiltrating subtypes. Measurable ZEB levels have even been detected in plasma and peritoneal fluid of patients with endometriosis and infertility, raising the prospect of ZEB-family proteins as circulating biomarkers.

Perhaps the most consequential section of the review concerns the bidirectional crosstalk between ZEB1 and sex steroid signalling. Endometriosis is a hormone-dependent disease, and its defining therapeutic problem is progesterone resistance: lesions fail to respond to the progestational drugs used to suppress them. The review marshals evidence that oestrogen, specifically 17β-estradiol, induces ZEB1 expression, and that ZEB1 in turn suppresses progesterone receptor pathways. This creates a self-reinforcing circuit in which the oestrogen-ZEB1 axis dismantles the molecular machinery that progesterone therapy depends upon. Experimental work has demonstrated that high ZEB1 expression accompanies 17β-estradiol-induced EMT in endometriotic cells, and parallel findings from other hormone-driven diseases reinforce the mechanism: in breast cancer, ZEB1 induces oestrogen receptor-α promoter hypermethylation and confers antiestrogen resistance, and ZEB-family members have been shown to regulate endocrine therapy sensitivity through both canonical and non-canonical routes. In endometriosis, EMT itself has been shown to contribute to the downregulation of progesterone receptor expression in lesions, and the near-uniform loss of progesterone receptor isoform B in ectopic tissue is a long-standing observation that the ZEB1 framework now helps to explain mechanistically.

The review also devotes substantial attention to the non-coding RNA dimension of ZEB1 regulation, describing a multilayered feedback architecture that locks the mesenchymal state in place. The miR-200 family of microRNAs normally targets the 3′ untranslated regions of ZEB1 and ZEB2 transcripts, holding EMT in check. In ectopic lesions, this double-negative feedback loop is subverted: ZEB1 represses miR-200 transcription, and the resulting loss of miR-200 pressure allows ZEB1 protein to accumulate. Long non-coding RNAs add another tier. The lncRNA AFAP1-AS1, for example, promotes EMT in endometriosis in a ZEB1-correlated manner, and the metastasis-associated transcript MALAT1 has been implicated in the same circuitry, with miR-200c suppressing endometriotic progression in vitro and in vivo by targeting it. Circular RNAs complete the picture. The circRNA circZFPM2 has been shown to promote EMT by sponging miR-205-5p and thereby releasing ZEB1 from repression, while hsa_circ_0063526 acts through the miR-141-5p/EMT axis and circATRNL1 acts upstream by upregulating the EMT cofactor YAP1. Together these competing endogenous RNA networks—a concept also validated in metastatic cancer by J Clin Invest work—build a ceRNA web that perpetuates ZEB1 expression long after the initial pro-EMT stimulus has passed.

The authors then connect ZEB1 to the two great downstream consequences of endometriotic lesions: chronic inflammation and fibrosis. Through interactions with the TGF-β pathway—upstream signals such as TGF-β1 activate SMAD2/3, which cooperate with ZEB1 to drive the mesenchymal programme—ZEB1-linked cells reshape the lesion microenvironment. Fibroblast-to-myofibroblast transdifferentiation, marked by α-smooth muscle actin expression, generates the dense extracellular matrix characteristic of endometriotic implants, and analogous MRTF-A–ZEB1–IRF9 axes have been documented in renal fibrosis. Inflammation completes the loop: pro-inflammatory cytokines such as TNF-α, IL-6 and IL-10, and peritoneal fluid cytokine profiles that differ across endometriosis subphenotypes, feed back into EMT signalling through MAPK, ERK, PI3K/AKT and NF-κB pathways, while immune evasion mechanisms—including indoleamine 2,3-dioxygenase-mediated suppression of natural killer cell cytotoxicity—shield ectopic tissue from immune clearance. ZEB1’s own roles in immune cell biology and in macrophage efferocytosis and mitochondrial dynamics add further dimensions to this immunological interplay.

A distinctive strength of the review is its engagement with modern genomics and the heterogeneity it has revealed. Single-cell transcriptomic analyses of endometriosis, published in Nature Genetics and the Journal of Pathology, have identified distinct hormonal, immunologic and inflammatory signatures among the cell populations constituting lesions, and spatial transcriptomics is beginning to map how intermediate fibroblast and myeloid cell distributions shape lesion architecture. ZEB1 expression, the authors note, is not uniform: it varies by lesion subtype, anatomical site and microenvironmental context, which helps explain why superficial peritoneal, ovarian endometrioma and deep infiltrating disease behave so differently and respond so unevenly to therapy. This heterogeneity argues strongly against a one-size-fits-all anti-ZEB1 strategy and supports the emerging precision-medicine framing of the oestrogen-ZEB1-TGF-β axis as the central therapeutic target.

The review is refreshingly candid about the translational paradox at the heart of any ZEB1-directed therapy. Far from being a purely pathological molecule, ZEB1 has indispensable physiological functions in the female reproductive tract. In vitro studies show that ZEB1 modulates endometrial receptivity through EMT in endometrial epithelial cells, and work in mice demonstrates that it promotes EMT of endometrial epithelium and plays a critical role in embryo implantation. ZEB1 is also detected in granulosa cells of women undergoing IVF, regulates wound angiogenesis and closure, participates in corneal homeostasis, and contributes to endometrial repair during menstruation through epithelial migration and mesenchymal–epithelial transition. Blanking ZEB1 systemically, therefore, risks impairing fertility, tissue regeneration and wound healing—the very outcomes clinicians are trying to protect. Any therapeutic strategy would need to be lesion-specific, temporally controlled and carefully titrated, perhaps by targeting upstream oestrogen-driven induction, the TGF-β/ALK5 arm, the non-coding RNA sponges, or post-translational stabilisation mechanisms such as ZEB1 acetylation, phosphorylation and ubiquitin-proteasome turnover via regulators like USP51 and SIAH1/2.

The authors also stress the need for better experimental models to establish causal rather than merely correlative relevance. shRNA- and siRNA-based knockdown of ZEB1 in endometriotic cells, three-dimensional patient-derived endometriosis models for drug evaluation, and multi-omics approaches that integrate transcriptomic, epigenomic and proteomic data—including recent ubiquitination-focused studies of endometriosis fibrosis—are all highlighted as tools that could convert the ZEB1 hypothesis into testable interventions. Biomarker development is another avenue: ZEB-family levels in plasma and peritoneal fluid, in combination with existing miRNA signatures, could one day support non-invasive diagnosis, a long-standing unmet need given that current detection still relies on laparoscopy.

Ultimately, the review’s central claim is that the oestrogen–ZEB1–TGF-β axis functions as a signalling hub through which the hormonal, inflammatory and epigenetic drivers of endometriosis converge and perpetuate one another. By identifying ZEB1 as the point of integration, the authors provide a mechanistic scaffold that could explain progesterone resistance, fibrotic progression and recurrence within a single framework, and they chart a cautious but concrete path toward mechanism-based, lesion-specific precision therapies. For a disease that has historically been managed with blunt hormonal and surgical instruments, the prospect of intervening at the level of a single, druggable transcriptional circuit represents one of the more compelling conceptual advances in endometriosis research in recent years.

In a finding that could reshape the search for new treatments against one of the deadliest gynecologic malignancies, researchers in Shanghai have identified the approved lung cancer drug tepotinib as a potent inhibitor of ovarian cancer growth, acting through an unexpected molecular target known as LY75. The study, published in the Journal of Ovarian Research, combines large-scale computational screening, structural biology, and preclinical testing to make a case for repurposing an existing medicine against a disease that urgently needs new options.

Ovarian cancer remains one of the most lethal cancers affecting women, largely because it is often diagnosed at an advanced stage and because resistance to platinum-based chemotherapy and PARP inhibitors eventually develops in most patients. High-grade serous ovarian cancer, the most common and aggressive subtype, has proven particularly stubborn, and survival rates have improved only marginally over recent decades. Against this backdrop, the idea of finding new uses for drugs that have already passed safety testing in humans, a strategy known as drug repurposing, has gained considerable traction. The new study demonstrates how modern computational tools can accelerate that process dramatically.

The research team, led by Yang Xiao, Wei Xia, and Yanan Song of Pudong Gongli Hospital and the Shanghai University of Medicine and Health Sciences, began by focusing on LY75, also known as CD205 or DEC205, a C-type lectin receptor best known for its role in antigen uptake by dendritic cells. Mining data from The Cancer Genome Atlas and the Human Protein Atlas, the investigators found that LY75 was significantly upregulated in ovarian cancer tissues compared with healthy tissue. More importantly, elevated LY75 expression correlated with shorter progression-free survival, marking the protein as both a potential biomarker of aggressive disease and an attractive therapeutic target.

With the target in hand, the team turned to structure-based virtual screening. Rather than testing thousands of compounds in the laboratory, they used the published crystal structure of the LY75 protein, deposited in the Protein Data Bank under the identifier 8K8H, as a template to computationally dock molecules from the TargetMol compound library. Docking predicts how well a small molecule fits into a binding pocket on a protein, but the researchers went considerably further. They applied MM/GBSA calculations, a method that estimates binding free energy by combining molecular mechanics forces with implicit solvent models, to rescore candidate poses. They also employed protein-ligand interaction fingerprints, or PLIF analysis, to compare the binding patterns of candidates against known interaction motifs, and ran ADMET predictions to filter out compounds likely to fail on absorption, metabolism, or toxicity grounds before any experiment was performed.

From this computational funnel, tepotinib emerged as the leading candidate. Tepotinib is an orally available small molecule approved in several countries for the treatment of non-small cell lung cancer harboring MET exon 14 skipping mutations, where it acts as a MET kinase inhibitor. Its appearance as a strong LY75 binder raised an obvious question: was any anti-cancer effect simply a consequence of MET inhibition? The team anticipated this concern and designed their study around it, measuring c-MET expression in their cell models, examining MET–LY75 co-expression patterns, and running parallel pharmacological controls with capmatinib, another selective MET inhibitor, to disentangle the two mechanisms.

The laboratory experiments delivered striking results. Tepotinib preferentially inhibited ovarian cancer cell lines with high LY75 expression, achieving half-maximal inhibitory concentrations, or IC₅₀ values, of 16.31 micromolar in SKOV3 cells and 18.91 micromolar in OVCAR-8 cells. In contrast, the drug showed markedly weaker activity against HO8910 cells, which express low levels of LY75, a dose-response pattern consistent with LY75 serving as the drug’s relevant target rather than an incidental one. To confirm a direct physical interaction, the researchers turned to surface plasmon resonance, a label-free optical technique that measures real-time binding between molecules immobilized on a sensor surface. The experiments confirmed that tepotinib binds LY75 directly, with a kinetic dissociation constant of 2.52 micromolar and a steady-state K_D of 3.74 micromolar, values indicating a specific and measurable interaction.

Perhaps the most intriguing mechanistic finding concerns what tepotinib does to the LY75 protein once bound. Treatment with the drug induced apoptosis in the sensitive cell lines, suppressed their migratory capacity, a process closely tied to metastatic spread, and downregulated LY75 protein levels. When the team probed how this downregulation occurred, they found that tepotinib accelerated LY75 degradation through a pathway that does not depend on the ubiquitin-proteasome system, the cell’s standard machinery for tagging unwanted proteins for destruction. Cycloheximide chase experiments, which block new protein synthesis and allow the decay rate of existing proteins to be measured, supported this conclusion. The identity of the alternative degradation route remains an open question, but the observation suggests tepotinib may engage lysosomal or autophagic pathways, a hypothesis that will require further work to confirm.

The in vivo evidence proved even more compelling. In mouse xenograft models implanted with SKOV3 ovarian cancer cells, oral administration of tepotinib markedly suppressed tumor growth, achieving a tumor inhibition rate of 79.6 percent. Analysis of the excised tumors showed reduced LY75 expression in the treated animals, consistent with the drug engaging its target in living tissue. All animal procedures were approved by the Institutional Animal Care and Use Committee of Shanghai Health Medical College and conducted in accordance with the ARRIVE guidelines for reporting animal research.

Crucially, the MET controls strengthened rather than weakened the case for LY75 as the operative target. Capmatinib, a structurally distinct MET inhibitor, failed to reproduce the full anti-tumor activity of tepotinib in the ovarian cancer models, and analyses of c-MET expression and MET–LY75 co-expression in patient datasets suggested that MET inhibition alone could not account for the magnitude of benefit observed. The authors therefore conclude that tepotinib’s effect in ovarian cancer reflects a genuine dual pharmacology, with LY75 binding and subsequent LY75 protein downregulation contributing substantially to its activity.

The implications of the study extend in several directions. First, it elevates LY75 from an immunological curiosity to a candidate therapeutic target in ovarian cancer, a protein whose abundance in tumors and association with poor prognosis make it a marker worth tracking clinically. LY75 has already attracted attention in oncology as a target for antibody-drug conjugates, given its presence on the surface of certain tumor cells and its efficient internalization, and the new findings add a small-molecule dimension to that conversation. Second, the work offers a template for computational drug repurposing: crystal-structure-guided docking, energy-based rescoring, interaction fingerprinting, and ADMET filtering followed by rigorous biochemical and in vivo validation. The approach identifies candidates in silico in a fraction of the time and cost of conventional screening campaigns.

Third, and most immediately, the results argue for clinical exploration of tepotinib in ovarian cancer, particularly in patients whose tumors express high levels of LY75. Because the drug is already approved and its safety profile in humans is documented, the path from laboratory finding to clinical trial is potentially shorter than for a de novo compound. The micromolar potencies observed in cell culture are modest by the standards of modern targeted therapy, and patients would likely require careful dosing studies, biomarker-based selection, and possibly drug combinations to translate the xenograft results into human benefit. Questions also remain about whether the ubiquitin-proteasome-independent degradation mechanism operates identically in human tumors and about the precise structural features of the tepotinib–LY75 interaction that could be optimized in next-generation analogs.

The study is not without limitations, as its authors acknowledge. The work relies on cell lines and xenografts rather than patient-derived models, and the correlation between LY75 expression and drug sensitivity, while suggestive, has been established across only a handful of cell lines. Prospective validation in patient-derived xenografts and organoids, ideally stratified by LY75 expression, would sharpen the biomarker hypothesis considerably. Nonetheless, the convergence of computational prediction, biochemical confirmation, mechanistic insight, and animal efficacy data makes this one of the more complete preclinical repurposing cases published for ovarian cancer in recent memory.

For a disease in which the therapeutic arsenal has expanded slowly and resistance is nearly universal, the prospect that a drug already sitting on pharmacy shelves could be redirected against a newly validated molecular target is the kind of story that resonates far beyond the laboratory. If follow-up studies and early-phase trials bear out these findings, tepotinib’s second act may prove more consequential than its first, and LY75 may take its place among the actionable targets of precision oncology.

A sweeping new narrative review published in the Journal of Translational Medicine is pulling back the curtain on one of the most overlooked aspects of chronic obstructive pulmonary disease: the devastating toll the disease takes on the body’s muscles, and the crucial — but complicated — role that exercise plays in fighting back. Led by Domenico Di Raimondo and colleagues at the University of Palermo, the review synthesizes decades of mechanistic research into how COPD reshapes both limb and respiratory muscles, how systemic inflammation may or may not be driving that damage, and why rehabilitation remains the most powerful non-drug therapy available despite nagging scientific uncertainties.

COPD has long been framed as a lung disease, defined by airway obstruction, chronic bronchitis, and emphysematous destruction of lung tissue. But clinicians have increasingly recognized that its most disabling features extend far beyond the chest. Patients with COPD frequently suffer from profound muscle wasting, particularly in the quadriceps, and this skeletal muscle dysfunction has emerged as a clinically relevant systemic manifestation of the disease. It contributes directly to the breathlessness that defines daily life for patients, reduces exercise tolerance, erodes quality of life, and — perhaps most tellingly — predicts mortality. A patient’s ability to stand from a chair or climb a flight of stairs, the review argues, may reveal as much about their prognosis as any spirometry reading.

The muscle changes in COPD are not simply the result of disuse, though physical inactivity certainly plays a role. Under the microscope, the peripheral muscles of these patients tell a story of deep biological remodeling. Muscle fibers shift in type, favoring fast-twitch, glycolytic fibers over the oxidative, fatigue-resistant fibers that sustain everyday activity. The oxidative capacity of the muscle falls, undermining the tissue’s ability to generate adenosine triphosphate efficiently and causing lactic acid to accumulate early during exertion — a process that patients experience as overwhelming leg fatigue long before their lungs reach their limits. Capillarization is impaired, reducing the delivery of oxygen and nutrients to working fibers. Mitochondria, the cellular power plants, show structural and functional dysfunction. Oxidative stress, driven by an excess of reactive oxygen species, damages proteins and membranes. And catabolic pathways, including the ubiquitin-proteasome system, are activated, actively breaking down muscle protein faster than the body can rebuild it.

One of the review’s central arguments is that not all muscle in COPD suffers equally, or in the same way. The quadriceps and other limb muscles typically show the destructive changes described above, but the diaphragm follows a different trajectory. The diaphragm in COPD patients is caught in a double bind: it is subject to intrinsic remodeling driven by chronic overload, yet it also works under a severe mechanical disadvantage caused by lung hyperinflation. As the lungs overinflate, the diaphragm flattens, shortens, and loses its mechanical leverage, making every breath more costly. In response, the diaphragm adapts in ways that differ from limb muscles — sometimes showing adaptive, rather than purely destructive, features as it struggles to meet the relentless demands of breathing through compromised lungs. This distinction between limb and respiratory muscle biology, the authors emphasize, matters enormously for understanding why patients with severe airflow obstruction can still have relatively preserved diaphragm function even as their legs waste away.

If the muscle pathology is the crime scene, systemic inflammation has long stood as the prime suspect. Elevated levels of inflammatory mediators such as tumor necrosis factor-alpha, interleukin-6, and C-reactive protein are commonly detected in COPD patients, and these signaling molecules are known to promote muscle protein breakdown, suppress anabolic signaling, and activate catabolic cascades. The review details the molecular routes by which inflammation can sabotage muscle: activation of nuclear factor-kappa B, engagement of the ubiquitin-proteasome system, interference with insulin-like growth factor-1 signaling, and disruption of insulin receptor substrate pathways that normally support muscle growth and glucose uptake. Yet the authors are refreshingly candid about the limits of this story. The true source of systemic inflammation in COPD is still debated — is it the lungs themselves, comorbid conditions, altered gut microbiota, or something else? — and, crucially, the causal contribution of systemic inflammation to muscle loss and dysfunction in COPD patients remains incompletely proven. Inflammation may be an amplifier rather than the sole architect of muscle decline.

Indeed, the review paints muscle wasting in COPD as a multifactorial process in which inflammation is only one ingredient. Ageing naturally erodes muscle mass and regenerative capacity. Multimorbidity — the coexistence of heart failure, chronic kidney disease, and other chronic conditions — compounds the burden. Malnutrition and inadequate caloric intake starve muscle tissue of the building blocks it needs. Hypoxemia, the low blood oxygen characteristic of advanced disease, impairs mitochondrial function and pushes muscle fibers toward glycolytic metabolism. Corticosteroid exposure, a frequent feature of COPD treatment during exacerbations, can further promote protein breakdown and impair anabolic signaling, a process partly mediated by enzymes such as 11 beta-hydroxysteroid dehydrogenase 1 that amplify glucocorticoid activity within muscle tissue. And physical inactivity, both a cause and a consequence of muscle decline, completes a vicious circle in which weakness breeds inactivity, which in turn breeds further weakness. Acute exacerbations of COPD accelerate this cycle dramatically, with each hospitalization potentially stripping away months of hard-won muscle mass and function.

Against this grim mechanistic backdrop, the review delivers its most clinically significant message: exercise training works. Pulmonary rehabilitation, built around structured exercise programs, is firmly supported as a cornerstone of non-pharmacological COPD management. The evidence base shows that exercise training improves muscle function, increases exercise capacity, alleviates symptoms, and restores functional autonomy — the ability of patients to manage their own daily lives. The mechanisms behind these gains are well understood from exercise physiology. Endurance and resistance training stimulate mitochondrial biogenesis through pathways involving peroxisome proliferator-activated receptor-gamma coactivator 1-alpha, the master regulator of oxidative metabolism. Training restores capillary density, shifts muscle fiber types back toward oxidative phenotypes, strengthens the antioxidant defense system against reactive oxygen species, and tips the balance between protein synthesis and breakdown back toward growth. Resistance training in particular offers a direct counterweight to catabolic signaling, mechanically stimulating muscle protein synthesis even in the presence of inflammatory stress.

But the review does not let exercise off the hook without scrutiny. One of its most provocative observations concerns inflammation. If exercise is so beneficial, and if inflammation is a key driver of muscle damage, one might expect training to measurably reduce circulating inflammatory biomarkers such as C-reactive protein, tumor necrosis factor-alpha, or interleukin-6. Yet the current evidence, the authors find, does not consistently demonstrate such a parallel reduction after training programs. Patients get stronger and more functional, but their blood inflammatory profiles often remain stubbornly unchanged. This disconnect raises a fundamental question about how exercise exerts its benefits in COPD: are the improvements driven by chronic adaptations within the cardiac, respiratory, and muscular systems themselves — local remodeling of muscle fibers, capillaries, and mitochondria — or do they also depend on systemic anti-inflammatory effects that clinical trials have so far failed to detect reliably?

The authors frame the resolution of this question as the field’s main unresolved challenge. Beyond the inflammation puzzle, the review identifies a set of pressing practical questions that clinicians and researchers have yet to answer definitively. What is the optimal training modality — endurance, resistance, interval training, or some combination? What intensity and duration produce the greatest and most durable muscle outcomes? And how should rehabilitation be tailored to the phenotype of the individual patient, given that a cachectic, hypoxemic patient with severe hyperinflation may need a fundamentally different program from a breathless but well-nourished patient with preserved muscle mass? The notion of phenotype-specific rehabilitation — matching the training prescription to the patient’s muscle biology, nutritional status, and inflammatory profile — emerges as a promising but still untested frontier.

The review also situates these findings within the broader translational landscape. Many of the molecular pathways it describes — the ubiquitin-proteasome system, the NOD-like receptor pyrin domain-containing protein 3 inflammasome, myostatin-related signaling, and the interplay between hypoxia-inducible factor 1 alpha and mitochondrial function — are potential drug targets. But the authors’ implicit conclusion is that no pharmacological shortcut will soon replace the accumulated, adaptive power of regular physical training. Muscle is plastic tissue, and the review suggests that the therapeutic leverage lies precisely in that plasticity, harnessed through carefully dosed and progressive exercise.

What makes the review timely is its honesty. Rather than inflating the anti-inflammatory credentials of exercise or overselling any single mechanism, it maps the terrain as it actually stands: muscle dysfunction in COPD is real, multifactorial, and deadly serious; exercise is genuinely effective; and the causal chain linking inflammation to muscle loss remains, frustratingly, an open question. For the millions of patients living with COPD worldwide, the practical takeaway is clear. Rehabilitation is not an optional add-on to inhaler therapy — it is a biological intervention that works at the level of the muscle fiber, the mitochondrion, and the capillary, even when the exact systemic chemistry of its benefits remains to be fully explained.

For researchers, the review is a call to arms. Future studies must disentangle the contribution of inflammation from the many other forces eroding muscle in COPD, identify biomarkers that predict who will respond best to which training modality, and design trials that test phenotype-matched rehabilitation strategies rather than one-size-fits-all programs. Until then, the message for clinical practice stands on remarkably firm ground: in COPD, what the lungs cannot fix, the muscles — given the right training — may yet do.

Two skeletons from the Indonesian island of Sulawesi had something strange going on in their mouths. Not cavities. Not the usual wear from a tough diet. Deep, rounded grooves cut into the teeth — a pattern no archaeologist had documented before, and one nobody could explain. The answer, published in Science Advances, pushes the known […]

An electrical fingerprint found on tiny particles in the blood may help detect signs of pancreatic cancer that are often overlooked, according to new research from Rice University. The researchers developed a device that separates these particles based on their electrical charge, making cancer-associated signals more visible.

These days, large language models are pushing the line between schizophrenic break and reality closer than ever before.

In a wild new post that’s going viral on X-formerly-Twitter, an enterprising young biochemist named Douglas Yao showcased a new drug he’s been developing with the aid of ChatGPT. He’s not employed by any pharma company, and his drug lab is setup on a couple folding tables in his garage.

Specifically, Yao enthuses about a new drug he calls “PAC-3310,” which he says is meant to treat schizophrenia. “It was designed by ChatGPT,” Yao explains, “and I synthesized it in a chemistry lab I built in my garage.”

The result is a small vial of yellow powder — the first sample of 3310, apparently — which Yao says is modeled after the recently-authorized antipsychotic Cobenfy, “but improved.”

This vial contains a new drug called PAC-3310. It was designed by ChatGPT, and I synthesized it in a chemistry lab I built in my garage.

PAC-3310 is a new selective M4 muscarinic receptor agonist for treating schizophrenia – similar to the recent breakthrough drug Cobenfry, but… pic.twitter.com/o7z6iLR50T

— Douglas Yao (@DouglasYaoDY) September 8, 2026

On his GitHub page, Yao boasts that he’s used AI to “design several thousand new small molecule drugs” over the past year, including a “new Alzheimer’s drug,” which he’s developing in addition to the schizophrenia treatment.

“I then taught myself synthetic chemistry, built a chem lab in my garage, and synthesized a hundred of them,” he continued. “I’m now testing these compounds in cell lines and mice.”

But whatever the one-man pharma lab hopes to accomplish is difficult to say. Yao references the fact that “drug developers typically spend tens of millions of dollars generating pre-clinical efficacy evidence for a new drug,” saying that “my approach can do this at 1/1000 the cost.” This seems to suggest dreams of someday manufacturing the various drugs on a massive scale for human consumption — a process that would take years of grueling and expensive work for a well-resourced drug lab, let alone a solo entrepreneur using a box fan as a fume hood.

For instance, to even approach the Food and Drug Administration’s “New Drug Application” — itself a costly 12-month process requiring inspection of the facility where the drug will be manufactured — one first has to conduct rounds of preclinical testing followed by three phases of clinical trials. Forget “tens of millions,” as Yao mentions; this is a process that can easily cost several billion.

Even then success is far from guaranteed, as only 13.8 percent of drugs that enter clinical trials go on to obtain full approval from the FDA.

While Yao might have been right at home in the free-wheeling research landscape of the 1970s, we no longer live in a world where a mad genius can synthesize hundreds of new drugs a year from a private lab. For one thing, the regulatory environment is much more demanding, as outlined above, to say nothing of the fact that all the low-hanging fruit has been picked from the vine decades ago.

When it comes to Yao’s ChatGPT-generated Alzheimer’s treatment, the landscape is particularly fraught. As one 2019 study found, no new drug has been approved to treat Alzheimer’s since 2003, and not for a lack of trying: as the study notes, over 200 proposed substances meant to treat the disease have either failed in clinical trials or been abandoned by their creators.

The graveyard of failed Alzheimer’s treatments is so vast that the renowned organic chemist Derek Lowe has built a blog on drug discovery which routinely features after-action reports on failed substances designed to treat the neurodegenerative disease. Simply put, to think that ChatGPT alone is enough to overcome these scientific and institutional hurdles is delusional.

Replies to Yao’s post were quick to point out the irony here, of using ChatGPT — which is well-known for leading vulnerable users down dangerous breaks from reality — to synthesize drugs to treat cognitive diseases like Alzheimer’s and schizophrenia.

“Hello schizophrenic, take this medicine that chatgpt made for you,” one poster quipped on X.

Another replied that “believing you single-handedly cured schizophrenia on a commercial laundry folding table in a garage is, ironically, a classic symptom of schizophrenia.”

More on ChatGPT: Man Obliterated When Court Obtains His ChatGPT Transcripts

The post Man Announces That He Has Synthesized a New Schizophrenia Treatment in His Garage, Based on a Formula Devised by ChatGPT appeared first on Futurism.

An unusual immune signature in lung cancer has led researchers toward a potential therapy involving tumor microbes and MAIT cells. Bacteria living inside lung tumors may be doing more than simply occupying the tumor environment. In preclinical research from the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy, researchers found that [...]

The pharmaceutical industry is trying to curtail your ability to complain about its behaviour with a new time limit, warns Dr Alan Black. But there's still time to make your voice heard about the changes.

The post The Pharmaceutical Industry is Trying to Curtail Your Ability to Complain About its Behaviour appeared first on The Daily Sceptic.